Erdem GÖKER
Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalı
Araştırma alanları: Sağlık Bilimleri, Tıp, Dahili Tıp Bilimleri, Onkoloji, İç Hastalıkları, Cerrahi Tıp Bilimleri, Kadın Hastalıkları ve Doğum, Temel Tıp Bilimleri, Radyasyon Onkolojisi, Temel Bilimler
Yayınlar
- Primary Tumor Histologic Regression and Immunotherapy Outcomes in Recurrent or Metastatic Melanoma (2026)
- Prominent Lymphovascular Space Invasion as an Independent Prognostic Factor in LVSI-Positive Endometrioid Endometrial Carcinoma: Evidence for a Novel Three-Tiered Classification (2026)
- Jinekolojik Kanserlerde İmmünoterapi (2026)
- Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer (2026)
- Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events (2026)
- Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group (2026)
- Scottish Inflammatory Prognostic Score Predicts Survival in Metastatic Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors (2026)
- Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study (2026)
- Evaluation of the Independent Prognostic Role of Malnutrition in the Survival of Patients With Gastric Cancer (2026)
- Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer (2026)
- Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours (2026)
- Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers (2026)
- Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group (2026)
- Feasibility and Safety of Rapid Drug Desensitization for Chemotherapy-Induced Maculopapular Eruptions (2026)
- A hidden danger in cancer patients: intestinal parasites (2026)
- Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group (2026)
- Treatment Outcomes and Toxicity of Cisplatin–Etoposide-Based Regimens and Carboplatin–Paclitaxel as Adjuvant Chemotherapy for Ovarian Adult Granulosa Cell Tumors: A Multicenter Retrospective Cohort Study (2026)
- PD ‐ L1 Expression in Uterine Mesenchymal Tumors: A Comparative Immunohistochemical Analysis (2026)
- Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group (2025)
- Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group (2025)
- Ten-Year Real-World Outcomes and Clinicopathologic Predictors of Recurrence in Adult Granulosa Cell Tumors: A Turkish Single-Center Experience (2025)
- Is Mandard tumor regression grade scoring sufficient for locally advanced rectal cancer? (2025)
- The Effect of Reiki Applied to Cancer Patients on Pain, Anxiety, and Stress Levels: A Randomized Controlled Study (2025)
- Efficacy and Safety of the Topotecan–Cyclophosphamide Regimen in Adult Metastatic Ewing Sarcoma: A Large, Multicenter, Real-World Study (2025)
- Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study (2025)
- Prognostic Value of Preoperative Lymphocyte-to-Monocyte Ratio in Patients with Recurrent Colorectal Cancer (2025)
- Is the Combination of Pembrolizumab and Regorafenib the Beginning of a New Era in the Treatment of Metastatic Colorectal Cancer? (2025)
- Palbosiklib–letrozol ve ribosiklib–letrozol kombinasyonlarının metastatik HR+ / HER2- meme kanserinde birinci basamak tedavide etkinlik ve güvenlilik açısından karşılaştırılması (2025)
- Metastatik pankreas kanserinde birinci basamak tedavi: FOLFIRINOX ile gemsitabin-sisplatin rejimlerinin etkinlik ve güvenlik açısından karşılaştırılması (2025)
- Ten-Year Real-World Outcomes and Clinicopathologic Predictors of Recurrence in Adult Granulosa Cell Tumors: A Turkish Single-Center Experience (2025)
- 2651P Real-world comparison of Cabozantinib and Sunitinib in advanced non–clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group (TOG) (2025)
- Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study (2025)
- Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study (2025)
- Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment (2025)
- Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study (2025)
- KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort (2025)
- P2.10.02 Developments in Treatment of Non-Small Cell Lung Cancer and Their Implications for National Practice.Registurk-Lung National Registry Study (2025)
- Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study (2025)
- Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer (2025)
- 16P Granulosa cell tumor of the ovary: 10-year follow-up data of 56 patients (2024)
- Pigmentation of the Tongue, Nails, and Gingiva Following Adriamycin Therapy: A Literature Review and Clinical Insights (2024)
- PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival? (2024)
- Cost of Hepatocellular Carcinoma from the Payer’s Perspective in Türkiye: Results of a Delphi Panel Analysis (2024)
- Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study (2024)
- Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group (2023)
- Pancreatic Resections for Oligometastatic Pancreatic Carcinoma (2023)
- Conversion Surgery for Unresectable Pancreas Cancer (2023)
- EFFECTS OF NICKEL CHLORIDE ON CELL MORPHOLOGY AND MIGRATION IN NON-SMALL CELL LUNG CANCER CELL LINES (2023)
- The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey (2023)
- Smoking Status in Relation to Clinicopathological Characteristics, Oncological Outcome, and Presence of Second Primary Lung Cancer in Patients with Bladder Cancer: A Population-based Registry Study (2023)
- Malnutrition as a Prognostic Factor in the Survival of Patients With Gastric Cancer (2023)
- Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience (2022)
- Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study (2022)
- Kanser İmmunoterapisi, Monoklonal Antikor ve Tirozin Kinaz İnhibitörü Alan Hastalarda Geç Tip Aşırı Duyarlılık Reaksiyonlarının İnsidans ve Tip Belirleme Çalışması (2021)
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial (2021)
- İmidazol nükleusunun hepatoselüler karsinoma hücre dizilerindeki antikanser etkileri (2021)
- Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients (2021)
- Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study. (2021)
- Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform (2021)
- Antifungal imidazole: Potential new antineoplastic agent-cytotoxic effects on non-small cell lung cancer cell lines (A549). (2021)
- The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study (2021)
- Sequential usage of imidazole followed by tamoxifen to enhance the anticancer effect of tamoxifen in estrogen receptor-positive breast cancer cell lines. (2021)
- Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations (2021)
- CYTOTOXIC EFFECT OF NICKEL CHLORIDE IN HEPATOCELLULAR CARCINOMA CELL LINES (2020)
- Boric Acid Treatment Decreases Cell Viability Of Hepatocellular Carcinoma Cells (2020)
- Synthesis and characterization of folic acid-chitosan nanoparticles loaded with thymoquinone to target ovarian cancer cells (2020)
- Synthesis and characterization of folic acid-chitosan nanoparticles loaded with thymoquinone to target ovarian cancer cells (2020)
- Karaciğer, safra kesesi ve safra yolu kanserlerinde epidemiyoloji ve sağ kalım özellikleri (2019)
- Korpus uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri (2019)
- Serviks uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri (2019)
- P2.02 Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial (2019)
- Nutritional Aspect of Cancer Care in Medical Oncology Patients (2019)
- Pancreatic resections for advanced M1-pancreatic carcinoma (2019)
- Tyrosine Kinase Inhibitors (2019)
- Tyrosine Kinase Inhibitors (2019)
- Ege Üniversitesi Hastanesi malign plevral mezotelyoma hastalarının epidemiyolojik ve genel sağ kalım özellikleri. (2019)
- Serviks uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri (2019)
- Over kanserinin epidemiyolojisi ve genel sağ kalım özellikleri (2019)
- Ege üniversitesi hastanesi malign plevral mezotelyoma hastalarının epidemiyolojik ve genel sağkalım özellikleri (2019)
- Korpusuterikanserlerininepidemiyolojivesağ kalımözellikleri (2019)
- Karaciğer, safra kesesi ve safra yolu kanserlerinde epidemiyoloji ve sağ kalım özellikleri (2019)
- Ege Üniversitesi Hastanesi malign plevral mezotelyoma hastalarının epidemiyolojik ve genel sağ kalım özellikleriEpidemiological and general survival characteristics of malign plevral mesothelioma patients in Ege University Hospital (2019)
- Effects of oral nutrition support on quality of life in cachectic pancreatic cancer patients (2018)
- Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial (2018)
- Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma (2018)
- P3.02b-003 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers (2017)
- Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study (2017)
- P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung (2017)
- Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study (2017)
- Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung (2016)
- Tyrosine Kinase Inhibitors (2016)
- Tyrosine Kinase Inhibitors (2016)
- 446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers (2016)
- Radyoişaretli Timokinon Glukronid Manyetik Nanoparçacıkların Akciğer Kanseri Üzerine İn Vitro/İn Vivo Biyolojik Davranışlarının Değerlendirilmesi (2016)
- LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy (2015)
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial (2015)
- A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (Ll8) (2014)
- Diagnosis of pregnancy after conservative management for adnexal torsion due to ovarian hyperstimulation in the same cycle (2014)
- Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting (2013)
- What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study (2013)